A new medication for multiple sclerosis made waves when research about its effectiveness debuted at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) back in October 2015. Now experts are calling this medication one of the greatest developments of the past year for the multiple sclerosis (MS) field.
Is your interest piqued yet? The medication in question, ocrelizumab from Genentech, is a second-generation monoclonal antibody which targets B-cells. A handful of Phase 3 studies recently tested ocrelizumab in individuals with either relapsing-remitting MS or primary progressive MS. The studies showed that this medication provided highly effective results, yet with fewer serious side effects than generally seen with the medications currently used for this disease.
Experts believe that this medication would make a difference if started early in the MS disease process, thus changing outcomes for relapsing-remitting MS in the future. Studies are indicative of similar benefits with primary progressive MS.
Although ocrelizumab is not yet FDA approved, it is expected to gain rapid approval as a first-line treatment for MS. What a great start to 2016 for the MS field.